BeiGene, Ltd. (HKG: 6160)
Hong Kong
· Delayed Price · Currency is HKD
107.10
+1.00 (0.94%)
Dec 24, 2024, 12:08 PM HKT
BeiGene Revenue
BeiGene had revenue of 7.35B CNY in the quarter ending September 30, 2024, with 39.54% growth. This brings the company's revenue in the last twelve months to 23.51B, up 50.22% year-over-year. In the year 2023, BeiGene had annual revenue of 2.46B with 73.65% growth.
Revenue (ttm)
23.51B CNY
Revenue Growth
+50.22%
P/S Ratio
n/a
Revenue / Employee
2.22M CNY
Employees
10,600
Market Cap
152.73B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.46B | 1.04B | 73.65% |
Dec 31, 2022 | 1.42B | 239.64M | 20.37% |
Dec 31, 2021 | 1.18B | 867.41M | 280.83% |
Dec 31, 2020 | 308.87M | -119.34M | -27.87% |
Dec 31, 2019 | 428.21M | 229.99M | 116.03% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionBeiGene News
- 3 days ago - BeiGene (BGNE) Announces Ticker Change to ONC Effective January 2025 - GuruFocus
- 4 days ago - BeiGene Ltd (BGNE) Announces Ticker Symbol Change to "ONC" in 2025 - GuruFocus
- 4 days ago - BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
- 14 days ago - BeiGene Ltd (BGNE) Announces Global Licensing Agreement for Novel Cancer Treatment - GuruFocus
- 14 days ago - BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor - Business Wire
- 16 days ago - Baker Bros. Advisors LP's Strategic Acquisition of BeiGene Ltd Shares - GuruFocus
- 17 days ago - BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets - Financial Post
- 17 days ago - BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets - Business Wire